This site is intended for patients in Great Britain (England, Scotland and Wales) who have been prescribed PIQRAY®▼ (alpelisib) + fulvestrant.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Why have I been prescribed Piqray?

You have been prescribed Piqray® (alpelisib) because your doctor believes you are of a specific subset of men or women who could benefit from this treatment.

PIQRAY is a treatment given to postmenopausal women, or men, who:1

  • have tested positive for a mutation, or abnormality, in a gene called PIK3CA – mutations in PIK3CA have been linked to breast cancer growth1–6
  • have hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer
  • have had a progression of their aBC following hormone-based therapy

Piqray is given in combination with another medicine called fulvestrant (see How do I take Piqray? for more information).1

Piqray is the brand name used for alpelisib.

Choose a topic below to learn more about Piqray

Resource banner image, woman on sofa

Browse through a range of helpful materials ranging from information about your diagnosis, Piqray treatment and living well with aBC


aBC, advanced breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; PIK3CA, phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha.


  1. PIQRAY® (alpelisib) Patient Information Leaflet. Available at: [Accessed November 2021].
  2. Croessmann S, et al. Clin Cancer Res. 2018;24(6):1426–1435.
  3. Sobhani N, et al. J Cell Biochem. 2018;119(6):4287–4292.
  4. Li SY, et al. Breast Cancer Res Treat. 2006;96(1):91–95.
  5. Lai YL, et al. Ann Surg Oncol. 2008;15(4):1064–1069.
  6. Mosele F, et al. Abstract 4895 presented at American Association for Cancer Research (AACR) Annual Meeting; 29 March–3 April 2019; Atlanta, GA, USA.

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See for how to report side effects.

UK | January 2022 | 147265